Kathy Warden - Merck Independent Director

MRK
 Stock
  

USD 88.93  0.26  0.29%   

  Director
Independent Director. We currently do not have informatin regarding Kathy Warden. This executive tanure with Merck Company is not currenlty determined.
Age: 49  Director Since 2020      
908 735-1500  www.merck.com

Kathy Warden Latest Insider Activity

Tracking and analyzing the buying and selling activities of Kathy Warden against Merck stock is an integral part of due diligence when investing in Merck. Kathy Warden insider activity provides valuable insight into whether Merck is net buyers or sellers over its current business cycle. Note, Merck insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merck'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Merck Management Efficiency

Merck Company has Return on Asset of 11.73 % which means that on every $100 spent on asset, it made $11.73 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 40.93 %, implying that it generated $40.93 on every 100 dollars invested. Merck management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to increase to 21.07, while Return on Average Assets are projected to decrease to 0.11. The current Total Liabilities is estimated to increase to about 67.8 B. The current Current Liabilities is estimated to increase to about 24.2 B
The company has 31.79 B in debt with debt to equity (D/E) ratio of 0.78, which is OK given its current industry classification. Merck Company has a current ratio of 1.37, which is typical for the industry and considered as normal. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Robert SteinIntel Corp
2016
John McCoyATT Inc
1999
Gregory SmithIntel Corp
2017
Stacy BrownPhilpotHP Inc
2015
Cynthia TaylorATT Inc
2013
Walter MasseyMcDonalds Corp
1998
Linda WolfWalmart
2005
Steven ReinemundWalmart
2010
Dan LittmanPfizer Inc
2018
Marissa MayerWalmart
2012
Beth MooneyATT Inc
2013
Shumeet BanerjiHP Inc
2011
Stacey MobleyHP Inc
2015
Risa LavizzoMoureyIntel Corp
2018
Yoky MatsuokaHP Inc
2019
Jaime PardoATT Inc
2008
Matthew RoseATT Inc
2021
Shantanu NarayenPfizer Inc
2019
Carl BassHP Inc
2015
Doron InbarAllovir
2009
Glenn HutchinsATT Inc
2014
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people. Merck Company (MRK) is traded on New York Stock Exchange in USA. It is located in 126 East Lincoln Avenue, Rahway, NJ 07065, United States and employs 67,000 people. Merck Company was previously known as MERCK INC and was traded on New York Stock Exchange under the symbol MRK. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Caroline Litchfield, Chief Financial Officer, Executive Vice President
Mirian GraddickWeir, Executive Vice President - Human Resources
Jannie Oosthuizen, Lead - Human Health U.S.
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Michael Klobuchar, Executive Vice President Chief Strategy Officer
Patricia Russo, Independent Director
David Williams, Executive Vice President Chief Information Chief Information and Digital Officer
Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing
Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
William Harrison, Lead Independent Director
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Deepak Khanna, Lead - Human Health International
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Risa LavizzoMourey, Independent Director
Thomas Glocer, Lead Independent Director
Craig Thompson, Independent Director
Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Arpa Garay, Lead - Human Health Global Marketing
Christine Seidman, Independent Director
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Stephen Mayo, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Clark Golestani, CIO and Executive VP
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Merck without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Merck Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Merck Company information on this page should be used as a complementary analysis to other Merck's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Merck Stock analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
1.54
Market Capitalization
226.8 B
Quarterly Revenue Growth YOY
0.28
Return On Assets
0.13
Return On Equity
0.43
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.